The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries
Open accessAbstract
OBJECTIVE: To review existing regulations and policies utilised by countries to enable patient access to orphan drugs. METHODS: A review of the literature (1998 to 2014) was performed to identify relevant, peer-reviewed articles. Using content analysis, we synthesised regulations and policies for access to orphan drugs by type and by country. RESULTS: Fifty seven articles and 35 countries were included in this review. Six broad categories of regulation and policy instruments were identified: national orphan drug policies, orphan drug designation, marketing authorization, incentives, marketing exclusivity, and pricing and reimbursement. The availability of orphan drugs depends on individual country's legislation and regulations including national orphan drug policies, orphan drug designation, marketing authorization, marketing exclusivity and incentives such as tax credits to ensure research, development and marketing. The majority of countries (27/35) had in place orphan drug legislation. Access to orphan drugs depends on individual country's pricing and reimbursement policies, which varied widely between countries. High prices and insufficient evidence often limit orphan drugs from meeting the traditional health technology assessment criteria, especially cost-effectiveness, which may influence access. CONCLUSIONS: Overall many countries have implemented a combination of legislations, regulations and policies for orphan drugs in the last two decades. While these may enable the availability and access to orphan drugs, there are critical differences between countries in terms of range and types of legislations, regulations and policies implemented. Importantly, China and India, two of the largest countries by population size, both lack national legislation for orphan medicines and rare diseases, which could have substantial negative impacts on their patient populations with rare diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Danaei, G., Ding, E. L., Mozaffarian, D., Taylor, B., Rehm, J., Murray, C. J. L., & Ezzati, M. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000058 · Cited by 2,860
Socio-economic burden of rare diseases: A systematic review of cost of illness evidence
Angelis, A., Tordrup, D., & Kanavos, P. (2015) · Health Policy · doi:10.1016/j.healthpol.2014.12.016 · Cited by 306
Assessing the economic challenges posed by orphan drugs
Drummond, M. F., Wilson, D. A., Kanavos, P., Ubel, P., & Rovira, J. (2007) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462307051550 · Cited by 279
Pricing and reimbursement of orphan drugs: the need for more transparency
Simoens, S. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-42 · Cited by 260
Rare diseases and orphan drugs
Melnikova, I. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3654 · Cited by 213
Rare diseases, orphan drugs and their regulation: questions and misconceptions
Tambuyzer, E. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3275 · Cited by 182
Georges, A., Bonneau, J., Bonnefont-Rousselot, D., Champigneulle, J., Rabès, J. P., Abifadel, M., Aparicio, T., Guenedet, J. C., Bruckert, E., Boileau, C., et al. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-1 · Cited by 175
Kumagi, T., & Heathcote, E. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-1 · Cited by 174
Cited by
Ferreira, C. R. (2019) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.61124 · Cited by 498
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357
Metadata
- Authors
- Gammie, T., Lu, C. Y., & Babar, Z. U.-D.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-10-09
- Volume
- 10
- Issue
- 10
- Pages
- e0140002
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2194206520
- Cited by
- 277
- References
- 40
- FWCI
- 55.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. https://app.cochat.ai/papers/10.1371/journal.pone.0140002
- The paper
- Gammie, T., Lu, C. Y., & Babar, Z. U.-D. (2015). Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. PLOS ONE. https://doi.org/10.1371/journal.pone.0140002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.